Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05630287 · ClinicalTrials.gov registry record · Phase 1
A Study of Absorption, Metabolism, Excretion, and Absolute Bioavailability of Carbon-14-Labelled [14C] Selpercatinib (LY3527723) in Healthy Male Participants
A Phase 1 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 1
- Development phase
- 12
- Enrollment target
NCT05630287 is a Phase 1 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 12 participants.
The verdict
NCT05630287, a Phase 1 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 12 participants
- Enrollment target
Study Summary
The main purpose of this study is to compare the amount of selpercatinib that gets into the blood stream and how long it takes the body to get rid of it and also to assess the pharmacokinetics (PK), metabolism, and routes and extent of elimination of selpercatinib in healthy male participants. The study will last up to 59 days (Part 1) or 46 days (Part 2) including screening and 7-day safety follow-up.
Interventions
- DRUG Selpercatinib
- DRUG [14C]-Selpercatinib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2018-08-01 |
| Est. Completion | 2018-09-24 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05630287
The ClinicalTrials.gov registry entry for NCT05630287 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Selpercatinib is the first listed.
NCT05630287 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05630287 about?
NCT05630287 is a clinical study titled "A Study of Absorption, Metabolism, Excretion, and Absolute Bioavailability of Carbon-14-Labelled [14C] Selpercatinib (LY3527723) in Healthy Male Participants". The main purpose of this study is to compare the amount of selpercatinib that gets into the blood stream and how long it takes the body to get rid of it and also to assess the pharmacokinetics (PK), metabolism, and routes and extent of elimination of selpercatinib in healthy male participants. The s...
What is the current status of trial NCT05630287?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 12 participants. The study started on 2018-08-01. Estimated completion is 2018-09-24.
What interventions are being tested in trial NCT05630287?
The interventions under investigation include: Selpercatinib (DRUG), [14C]-Selpercatinib (DRUG).
Who is sponsoring clinical trial NCT05630287?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.